Join +750K new investors every month who copy stock picks from billionaire's portfoliosSign Up Free

Teleflex Launches Advanced Percutaneous Surgical System

Published 08/17/2016, 06:45 AM
Updated 07/09/2023, 06:31 AM
NTUS
-
IDXX
-
AORT
-
TFX
-

Following the U.S. Food and Drug Administration’s (FDA) clearance, Teleflex Incorporated (NYSE:TFX) announced the launch of its second generation Percuvance Percutaneous Surgical system. This system has been recognized as the first clinical laparoscopic procedure in the U.S. recently. Next month, a chain of surgical trials will be performed in leading institutions in the U.S.

Percuvance Percutaneous Surgical system is used to execute laparoscopic procedures. It comprises reusable handles and seven disposable 5mm interchangeable tool tips which include graspers, scissors, dissector, electrocautery tools, and a Weck Hem-o-lok Polymer Ligation Clip Applier. The system helps in percutaneous insertion without the insertion trocar.

With nearly 3 million laparoscopic procedures performed each year in the U.S., we expect Teleflex to gain considerable market traction with the recent launch.

In this regard, we note that traditional laparoscopy is associated with the insertion of trocars, which becomes painful for patients while percutaneous laparoscopy is devoid of trocars which assures less trauma for patients. On the contrary, the percutaneous laparoscopy, promoted by Teleflex helps overcome complications in the surgery. The procedure is much less invasive compared to the traditional one.

The latest system can be used in both common and advanced general laparoscopic procedures like cholecystectomy, upper gastrointestinal, gastric, bariatric, colorectal and hernia. According to the company, the latest offering is more versatile and allows even less invasive procedures than its first-generation 5 mm device.

Notably, the first generation Percuvance system was launched in Mar 2015 and has already been used by 150 surgeons in the U.S. and EMEA region.

Management is confident that the Percuvance System will turn out to be the new standard of care in laparoscopic surgery. Additionally, it is expanding its sales force to promote the device among surgeon. We believe that this new system will propel top-line growth at the company.

Zanks Rank and Other Key Picks

Telefex carries a Zacks Rank #2 (Buy).

Other favorably ranked stocks in the same space include IDEXX Laboratories (NASDAQ:IDXX) , Natus Medical (NASDAQ:BABY) and CryoLife (NYSE:CRY) . All the three companies sport a Zacks Rank #1 (Strong Buy).



TELEFLEX INC (TFX): Free Stock Analysis Report

NATUS MEDICAL (BABY): Free Stock Analysis Report

IDEXX LABS INC (IDXX): Free Stock Analysis Report

CRYOLIFE INC (CRY): Free Stock Analysis Report

Original post

Zacks Investment Research

Latest comments

Loading next article…
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.